SCHEMBL3237371

SCHEMBL3237371

O=C(O)CS(=O)(=O)Cc1ccc(C(=O)O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.56
HSD17B10 Q99714 1/20 0.56
ALDH1A1 P00352 2/20 0.48
CA12 O43570 4/20 0.47
CA1 P00915 4/20 0.47
CA2 P00918 4/20 0.47
CA9 Q16790 4/20 0.47
CA14 Q9ULX7 4/20 0.47
CA3 P07451 2/20 0.47
CA6 P23280 2/20 0.47
CA5A P35218 2/20 0.47
CA7 P43166 2/20 0.47
CA5B Q9Y2D0 2/20 0.47
CA4 P22748 1/20 0.47
CA13 Q8N1Q1 1/20 0.47
KMT2A Q03164 4/20 0.47
CYP2C19 P33261 1/20 0.47
TP53 P04637 1/20 0.46
MMP12 P39900 1/20 0.45
MMP13 P45452 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11581819 0.88 TSHR (0.58) TSHRHSD17B10ALDH1A1CA12CA1
SCHEMBL2338220 0.82 CA2 (0.52) HSD17B10ALDH1A1CA1CA2KMT2A
SCHEMBL1018823 0.82 ALDH1A1 (0.61) TSHRHSD17B10ALDH1A1CA12CA2
SCHEMBL16489290 0.82 PRSS1 (0.51) ALDH1A1KMT2A
SCHEMBL498617 0.82 ALDH1A1 (0.56) TSHRHSD17B10ALDH1A1CA1CA2
SCHEMBL1137128 0.81 LMNA (0.47) HSD17B10ALDH1A1KMT2ATP53MMP12
SCHEMBL3267907 0.81 KMT2A (0.69) TSHRHSD17B10ALDH1A1KMT2ACYP2C19
SCHEMBL2338295 0.81 KMT2A (0.46) HSD17B10ALDH1A1CA1CA2KMT2A
SCHEMBL2337040 0.81 KMT2A (0.46) HSD17B10ALDH1A1KMT2AMMP12MMP13
SCHEMBL831127 0.81 KMT2A (0.51) KMT2AMMP12MMP13POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735620-B2 Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders EPR PHARMACEUTICALS PVT. LTD (IN) 2014-05-27 US disclosed
US-20100152491-A1 PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS EPR PHARMACEUTICALS PVT.LTD 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152491-A1 PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS PCNA, CDC25B, CCNB1 TSHR 3396/4885HSD17B10 1551/4885ALDH1A1 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.